NYU Medical Center, Rosetta Genomics partnering to develop product for early detection of mesothelioma

23

Apr
2007

Rosetta Genomics and NYU Medical Center are partnering to develop a line of products for the early detection of mesothelioma and lung cancers, according to a April 23, 2007 press release by Rosetta. The early detection test would use a simple blood test to check for microRNAs in the blood of people who have been exposed to asbestos fibers. Mesothelioma is a form of cancer caused by asbestos exposure, in which malignant cells develop on the mesothelium, a protective lining that covers the lungs, abdomen, heart, and other organs of the body. Early detection of mesothelioma could result in more effective treatment options in fighting the dise�ase

email this page print this page permanent link

Related News

Baron & Budd, P.C.:
Since 1977, the law firm of Baron & Budd, P.C. has championed the rights of people and communities harmed by corporate misconduct. With over 50 attorneys and offices in Texas, California, and Louisiana, Baron & Budd enjoys a national reputation as a leader of the plaintiffs’ bar. The firm represents individuals with mesothelioma and other diseases caused by asbestos and injuries caused by other toxic substances and pharmaceuticals. The firm also represents water authorities seeking clean-up costs for drinking water contamination; securities investors and governmental entities defrauded by corporate wrongdoing; and consumers. For more information about Baron & Budd, call 800-222-2766 or contact us via our secure form.

 
Other Offices:
  • Baton Rouge, LA
  • Cleveland, OH
  • Beverly Hills, CA
  • Austin, TX
Main Office:
3102 Oak Lawn Avenue, Suite 1100
Dallas, TX 75219
For nearly 30 years, the law firm of Baron & Budd, P.C. has fought to safeguard the rights of mesothelioma victims and their families. MesotheliomaNews.com is a public service of Baron & Budd, P.C.

© 2008, Baron & Budd, P.C.